Securities Code: 002294 Securities Abbreviation: Lifetai Number: 2026-033 Shenzhen Lifetai Pharmaceutical Co., Ltd. Announcement on Proposed Re-appointment of 2026 Annual Auditor
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
Special Notes:
- The audit opinion for the Company's 2025 fiscal year was a standard audit opinion.
- This re-appointment does not involve a change of accounting firm.
- The Audit Committee and the Board of Directors have no objections to the proposed re-appointment of the accounting firm.
- The re-appointment of the accounting firm complies with the "Measures for the Selection and Appointment of Accounting Firms by State-owned Enterprises and Listed Companies" (Cai Kuai [2023] No. 4) issued by the Ministry of Finance, the State-owned Assets Supervision and Administration Commission of the State Council, and the China Securities Regulatory Commission.
Shenzhen Lifetai Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 18th meeting of the Sixth Board of Directors on April 17, 2026, and approved the "Proposal on Re-appointing the Company's 2026 Annual Auditor." It is proposed to re-appoint Da Xin Certified Public Accountants (Special General Partnership) as the Company's 2026 annual auditor for a term of one year, with a proposed audit fee of RMB 1.1 million (including RMB 850,000 for financial report audit and RMB 250,000 for internal control audit). This proposal will be submitted to the 2025 Annual Shareholders' Meeting for review. The specific details are as follows:
I. Explanation of the Matter of Re-appointing the Accounting Firm
Da Xin Certified Public Accountants (Special General Partnership) (hereinafter referred to as "Da Xin" or "Da Xin Certified Public Accountants") is an accounting firm that meets the requirements of the "Securities Law" and possesses sufficient independence, professional competence, and investor protection capabilities. During its tenure as the Company's 2025 auditor, it strictly adhered to the relevant regulations of the Chinese Certified Public Accountants' Independent Auditing Standards, maintained an independent, objective, and fair attitude, and successfully completed the annual audit services entrusted by the Company, demonstrating good professional ethics and integrity. The issued audit report fully reflects the Company's actual situation. To maintain the continuity of audit work, upon the recommendation of the Audit Committee, the Board of Directors proposes to re-appoint Da Xin Certified Public Accountants (Special General Partnership) as the Company's 2026 annual auditor for a term of one year, with a proposed audit fee of RMB 1.1 million (including RMB 850,000 for financial report audit and RMB 250,000 for internal control audit).
This matter still needs to be submitted to the Company's 2025 Annual Shareholders' Meeting for review.
II. Basic Information of the Proposed Accounting Firm